(Q33933213)

30 July 2017

title

Bispecific antibodies for treatment of cancer in experimental animal models and man. (English)

1 reference

30 July 2017

de Leij L

1

1 reference

30 July 2017

Molema G

series ordinal

2

1 reference

30 July 2017

Helfrich W

series ordinal

3

1 reference

30 July 2017

Kroesen BJ

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

Advanced Drug Delivery Reviews

30 July 2017

published in

1 reference

30 July 2017

volume

31

1 reference

30 July 2017

issue

1-2

1 reference

30 July 2017

page(s)

105-129

1 reference

Monoclonal antibodies in diagnosis and therapy

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Immunotherapy with monoclonal antibodies in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Hybrid hybridomas and their use in immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Target cell-induced T cell activation with bi- and trispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Directed effector cells selectively lyse human tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific F(ab′γ)3 antibody derivatives for redirecting unprimed cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Preliminary trial of specific targeting therapy against malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Characterization of a new monoclonal anti-Fcγ RII antibody, AT10, and its incorporation into a bispecific F(ab′)2 derivative for recruitment of cytotoxic effectors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Toward the production of bispecific antibody fragments for clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

High level secretion of a humanized bispecific diabody from Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Phage antibodies: filamentous phage displaying antibody variable domains

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Preparation of a bispecific F(ab')2 targeted to the human IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Crystal structure of a diabody, a bivalent antibody fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Human squamous cell lung cancers express increased epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Epidermal growth factor receptors in lung tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Characterization of the human tumor and normal tissue reactivity of the KS1/4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD29.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

The use of hybrid hybridomas to target human cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Cytotoxicity mediated by human Fc receptors for IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Activation of natural killer cells via the p75 interleukin 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Tumor Therapy by Immune Recruitment with Bispecific Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

A "minimal signal-stepwise activation" analysis of functional maturation of T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Role of cross-linking in stepwise activation of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Hybrid antibodies can target sites for attack by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Spontaneous remission of renal cell carcinoma: a case report and immunological correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Regulation of lymphokine expression in T cell activation. I. Rapid loss of interleukin-specific RNA after removal of the stimulating signal

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: III. Activation of resting T cells and tumor neutralization induced by bispecific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Interleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

The role of apoptosis in antibody-dependent cellular cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

T cell activation determined by T cell receptor number and tunable thresholds.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Serial triggering of many T-cell receptors by a few peptide-MHC complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

In vivo administration of anti-CD3 prevents malignant progressor tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Activation of human T cells in vivo following treatment of transplant recipients with OKT3.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

T cell responses are governed by avidity and co-stimulatory thresholds

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Duration of TCR stimulation determines costimulatory requirement of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

T cell activation and cytokine production in anti-CD3 bispecific antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

ICAM-1-independent lymphocyte transmigration across high endothelium : Differential up-regulation by interferon γ, tumor necrosis factor-α and interleukin 1β

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Lymphocytes stimulated with recombinant human interleukin-2: relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Neurogenic amplification of immune complex inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Bispecific antibodies in lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Modulation of cancer patients' immune responses by anti-idiotypic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

A novel epitope of the LFA-1 antigen which can distinguish killer effector and suppressor cells in human CD8 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acute Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Serum gangliosides as endogenous immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Induction of programmed cell death and immunosuppression by exogenous sphingolipids are separate processes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Immunosuppression by YAC-1 lymphoma: role of shed gangliosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

Role of Fc gamma receptors in cancer and infectious disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900096-3

7 January 2021

10.1016/S0169-409X(97)00096-3

Identifiers

DOI

1 reference

30 July 2017

1 reference